公开(公告)号：US20240350524A1

公开(公告)日：2024-10-24

申请号：US18627239

申请日：2024-04-04

申请人： ABBVIE INC.

发明人： Ahmed H. SALEM ,  Johannes WOLFF ,  John HAYSLIP

IPC分类号： A61K31/706 ,  A61K31/496 ,  A61P35/02

CPC分类号： A61K31/706 ,  A61K31/496 ,  A61P35/02

摘要： The invention described herein relates to relates to dosing methods for a human subject with acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation, comprising administering to a human subject venetoclax in combination with azacitidine, wherein the human subject has previously undergone allogeneic hematopoietic stem cell transplantation.

公开(公告)号：US20240317754A1

公开(公告)日：2024-09-26

申请号：US18270009

申请日：2021-09-15

申请人： SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY ,  SUN YAT-SEN UNIVERSITY

发明人： Xumu ZHANG ,  Deyin GUO ,  Guanguan LI ,  Liu CAO ,  Yingjun LI ,  Tiefeng XU ,  Yanxi JI ,  Qifan ZHOU ,  Yujian YANG ,  Tiaozhen ZHU

IPC分类号： C07D487/04 ,  A61K31/706 ,  A61P31/14

CPC分类号： C07D487/04 ,  A61K31/706 ,  A61P31/14

摘要： Provided are methods for treating coronavirus infections by administering modified nucleosides, ester and amino acid ester prodrugs of nucleoside, their pharmaceutically acceptable salts, and drug combination thereof, of Formula (I). The compounds, combination, and methods provided are particularly useful for preventing, mitigating, or treating coronavirus infections or cytopathic effects resulting from the replication or reproduction of coronaviruses and their variants, including SARS-CoV-2.

公开(公告)号：US20240309038A1

公开(公告)日：2024-09-19

申请号：US18259146

申请日：2021-12-22

申请人： GALECTO BIOTECH AB

发明人： Fredrik ZETTERBERG ,  Kristoffer PETERSON ,  Ulf NILSSON

IPC分类号： C07H19/04 ,  A61K31/7056 ,  A61K31/706

CPC分类号： C07H19/04 ,  A61K31/7056 ,  A61K31/706

摘要： A D-galactopyranose compound of formula (1)






wherein
the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of disorders relating to the binding of a galectin-3 to a ligand in a mammal. The disorders include inflammation; fibrosis; endometriosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; scleroderma; systemic sclerosis; septic shock; cancers; metastasising cancers; systemic lupus erythematosus; metabolic disorders; coagulopathies; cardiovascular disorders; heart disease; heart failure; and eye diseases; atherosclerosis; endocrine disorders; metabolic diseases; insulin resistance; obesity; Diastolic HF; atrophic diseases in the brain; disorders related to transplantation in organs; acute burn; acute inflammatory reaction; chronic acute skin graft rejection; chronic scarring; asthma and other interstitial lung diseases; Otosclerosis, mesothelioma; post-surgery disorders; toxin exposure disorders; Tissue injury; congenital hepatic fibrosis; hereditary fibrosing poikiloderma; liver disorders; and neurodegenerative disorders.

公开(公告)号：US20240299492A1

公开(公告)日：2024-09-12

申请号：US18279451

申请日：2022-03-04

申请人： Shattuck Labs, Inc.

发明人： Taylor SCHREIBER ,  Suresh DE SILVA ,  George FROMM

IPC分类号： A61K38/17 ,  A61K31/282 ,  A61K31/337 ,  A61K31/439 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/635 ,  A61K31/69 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  A61K33/243 ,  A61K38/19 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K38/1774 ,  A61K31/282 ,  A61K31/337 ,  A61K31/439 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/635 ,  A61K31/69 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  A61K33/243 ,  A61K38/191 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00

摘要： The present disclosure relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer.

公开(公告)号：US20240299325A1

公开(公告)日：2024-09-12

申请号：US18667471

申请日：2024-05-17

申请人： ENZENE BIOSCIENCES LIMITED

发明人： Himanshu GADGIL ,  Abir BANERJEE ,  Arindam CHAKRABORTY ,  Mazin ADENWALA

IPC分类号： A61K31/194 ,  A61K31/165 ,  A61K31/17 ,  A61K31/198 ,  A61K31/337 ,  A61K31/475 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7076 ,  A61K38/12 ,  A61P7/00

CPC分类号： A61K31/194 ,  A61K31/165 ,  A61K31/17 ,  A61K31/198 ,  A61K31/337 ,  A61K31/475 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7076 ,  A61K38/12 ,  A61P7/00

摘要： The present invention relates to succinic acid and its derivative(s) of Formula (I), their pharmaceutically acceptable salts, polymorphs, solvates, hydrates, co-crystals, isomers and solvates thereof as an active pharmaceutical ingredient for the treatment of haematological disorder(s). The present invention further relates to compounds of Formula (I), for the treatment of disorders selected from dengue, idiopathic thrombocytopeniarpura (ITP), anaemia and chemotherapy induced myelosuppression. The present invention also relates to use of succinic acid for the treatment of haematological disorder(s), wherein succinic acid is extracted from Papaya leaves. The present invention also provides pharmaceutical compositions comprising succinic acid and its derivative(s) of Formula I and methods of treating haematological disorder(s).

公开(公告)号：US12084472B2

公开(公告)日：2024-09-10

申请号：US17185653

申请日：2021-02-25

申请人： Ardelyx, Inc.

发明人： Jason G. Lewis ,  Michael Robert Leadbetter ,  Jeremy Caldwell ,  Dean Dragoli ,  Noah Bell ,  Jeffrey W. Jacobs ,  Patricia Finn ,  Rakesh Jain ,  Tao Chen ,  Matthew Siegel

IPC分类号： A61K31/444 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/553 ,  A61K31/706 ,  A61K45/06 ,  C07B59/00 ,  C07C409/12 ,  C07D213/30 ,  C07D213/38 ,  C07D213/80 ,  C07D213/81 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/08 ,  C07H15/04 ,  C07H15/18 ,  C07H15/234 ,  C07H15/26

CPC分类号： C07H15/26 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/553 ,  A61K31/706 ,  A61K45/06 ,  C07B59/002 ,  C07C409/12 ,  C07D213/30 ,  C07D213/38 ,  C07D213/80 ,  C07D213/81 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/08 ,  C07H15/04 ,  C07H15/18 ,  C07H15/234 ,  C07B2200/05

摘要： The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula:






where R1, R2, R2′, R3, R4, X1, X2, X3, X4, Q, and n are described herein.

公开(公告)号：US20240277749A1

公开(公告)日：2024-08-22

申请号：US18568219

申请日：2022-06-10

申请人： NANEXA AB

发明人： Anders JOHANSSON ,  Mårten ROOTH ,  Erik LINDAHL ,  Joel HELLRUP ,  David WESTBERG

IPC分类号： A61K31/706 ,  A61K9/00 ,  A61K9/10 ,  A61K9/50 ,  A61P35/00 ,  C23C16/40 ,  C23C16/455

CPC分类号： A61K31/706 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/501 ,  A61K9/5073 ,  A61P35/00 ,  C23C16/407 ,  C23C16/45555

摘要： There is provided a pharmaceutical formulation that is useful in the treatment of myelodysplastic syndrome, comprising a plurality of particles suspended in an aqueous carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 μm; and (b) comprise solid cores comprising azacitidine, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is between at least 1:6 and up to and including about 6:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of azacitidine to treat myelodysplastic syndrome without a burst effect.

公开(公告)号：US20240269278A1

公开(公告)日：2024-08-15

申请号：US18691846

申请日：2022-09-29

申请人： Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group ,  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

发明人： Anqi Yang ,  Xiquan Zhang ,  Ding Yu ,  Peng Lv ,  Xunqiang Wang ,  Xin Tian ,  Qin Chen

IPC分类号： A61K39/395 ,  A61K31/706 ,  A61K39/00 ,  A61P35/00 ,  A61P35/02 ,  C07K16/28

CPC分类号： A61K39/39558 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02 ,  C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

摘要： An anti-CD47 antibody for combined treatment of a blood tumor. Provided are the use of the anti-CD47 antibody and a second therapeutic agent in the preparation of a drug for treating a blood tumor in a subject. Provided is a method for treating a blood tumor in a subject, comprising administering a therapeutically effective amount of the anti-CD47 antibody and the second therapeutic agent to a subject. Also provided are a pharmaceutical combination comprising the anti-CD47 antibody and the second therapeutic agent, and a kit.

公开(公告)号：US20240261292A1

公开(公告)日：2024-08-08

申请号：US18560233

申请日：2022-05-09

申请人： Janssen Pharmaceutica NV

发明人： Nikki Daskalakis ,  Christina Diane Guttke ,  Min Chul Kwon ,  Lucille Angela Ferrante ,  Kathryn Elizabeth Packman ,  Eva Christine Pietsch ,  Ulrike Philippar ,  Tinne Ann J. Verhulst ,  Sumia Ali-Ahmed ,  Balpreet Bhogal ,  Yu Sun ,  Wei Cai ,  Xuedong Dai ,  Olivier Alexis Georges Querolle ,  Johannes Wilhelmus J. Thuring ,  Yingtao Liu ,  Lianzhu Liu ,  Yanping Xu ,  Liqiang Fu ,  Ming Li ,  Lichao Fang ,  Xiangjun Deng ,  Alicia Tee Fuay Ng ,  Nicolas Freddy J. Darville ,  Vineet Pande

IPC分类号： A61K31/53 ,  A61K31/4725 ,  A61K31/553 ,  A61K31/704 ,  A61K31/706 ,  A61P35/00

CPC分类号： A61K31/53 ,  A61K31/4725 ,  A61K31/553 ,  A61K31/704 ,  A61K31/706 ,  A61P35/00

摘要： Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows:




wherein R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 and n4 are defined herein.

公开(公告)号：US20240173347A1

公开(公告)日：2024-05-30

申请号：US18522970

申请日：2023-11-29

申请人： ACCURI, LLC

发明人： Boying DUN ,  Jin-Xiong SHE

IPC分类号： A61K31/7084 ,  A61K31/198 ,  A61K31/455 ,  A61K31/7004 ,  A61K31/7012 ,  A61K31/706 ,  A61P43/00

CPC分类号： A61K31/7084 ,  A61K31/198 ,  A61K31/455 ,  A61K31/7004 ,  A61K31/7012 ,  A61K31/706 ,  A61P43/00

摘要： Provided herein are compositions and methods of use thereof for efficiently raising NAD levels in a subject in need thereof, and improving the body's functions associated with low NAD levels. The composition comprises NAD precursors and additional components that elevate NAD levels and improve mitochondrial and cellular functions. The additional components include NAD+, NADH, D-ribose and creatine monohydrate, nicotinamide and/or nicotinic acid (NA) and may be added to the formulation to further enhance the composition's efficacy.